Literature DB >> 18505682

Laboratory, clinical and therapeutic aspects of acquired hemophilia A.

Massimo Franchini1, Giovanni Targher, Martina Montagnana, Giuseppe Lippi.   

Abstract

Acquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed against clotting factor VIII and associated with an increased morbidity and mortality. This disease occurs most commonly in the elderly, and although it may be associated with a variety of underlying pathological conditions, up to 50% of reported cases remain idiopathic. In this review, we report the present knowledge on the most important laboratory, diagnostic and clinical aspects of acquired hemophilia A. Moreover, we focus on the most recent advances in the treatment of this disorder, which is primarily aimed to control bleeding episodes and to eradicate the autoantibody production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505682     DOI: 10.1016/j.cca.2008.05.003

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

Review 2.  The use of desmopressin in acquired haemophilia A: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

3.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

Review 4.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

6.  Acquired Hemophilia A: Experience of a Tertiary Care Institute from North India.

Authors:  Narender Kumar; Sweta Rajpal; Jasmina Ahluwalia; Sunil Bose; Varun Uppal; Neelam Varma; Pankaj Malhotra; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-18       Impact factor: 0.900

Review 7.  Diagnosis, laboratory aspects and management of acquired hemophilia A.

Authors:  Vincenzo Toschi; Francesco Baudo
Journal:  Intern Emerg Med       Date:  2010-04-21       Impact factor: 3.397

8.  Acquired haemophilia A: the importance of early recognition in cases of spontaneous bleeding in the elderly.

Authors:  Neeral Patel; Zoe Wyrko; Syeda Naqvi; Adam P Croft
Journal:  BMJ Case Rep       Date:  2014-11-20

9.  A rare case of acquired hemophilia A associated with myelodysplastic syndrome.

Authors:  Mihir Raval; Rekha Kallamadi; Dinesh Bande
Journal:  Int J Clin Exp Med       Date:  2012-06-15

10.  Acquired haemophilia A initially diagnosed as angioedema.

Authors:  Asmeret Demissie; Lokesh Shahani; Aziz Khan; Meghna Desai
Journal:  BMJ Case Rep       Date:  2013-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.